Curative brachytherapy for prostate cancer in African-Caribbean patients: A retrospective analysis of 370 consecutive cases
Abstract Purpose Prostate cancer is the most frequent malignancy in African-Caribbean men, a population sharing common genetic traits with African-American (AA) but presenting also genomic and epidemiologic specificities. Despite socioeconomic disparities with French mainland, all patients were trea...
Gespeichert in:
| Veröffentlicht in: | Brachytherapy 2017-03, Vol.16 (2), p.342-347 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 347 |
|---|---|
| container_issue | 2 |
| container_start_page | 342 |
| container_title | Brachytherapy |
| container_volume | 16 |
| creator | Atallah, V Leduc, N Creoff, M Sargos, P Taouil, T Escarmant, P Vinh-Hung, V |
| description | Abstract Purpose Prostate cancer is the most frequent malignancy in African-Caribbean men, a population sharing common genetic traits with African-American (AA) but presenting also genomic and epidemiologic specificities. Despite socioeconomic disparities with French mainland, all patients were treated within the French state–financed equal-access health care system. In this study, we report biochemical outcomes of patients treated by brachytherapy in our department from 2005 to 2014 in an African-Caribbean population. Methods and Materials Three hundred seventy consecutive patients receiving125 I brachytherapy as a curative treatment for early-stage (localized) disease between 2005 and 2014 were recorded. Selected patients presented with low-risk disease: initial prostate-specific antigen (PSA) |
| doi_str_mv | 10.1016/j.brachy.2016.11.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1853362315</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1538472116306043</els_id><sourcerecordid>1853362315</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-dcfb3fdff801946e11d80c3c00c28ea5e8591b55f019dbb67359f675075bb35e3</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxS0EomXhGyDkI5cETxznDwek1YoWpEocgLNlO2PVSzYJdlIp6pdntikcuPRkj-a9Gb3fMPYWRA4Cqg_H3Ebjbte8oCoHyIWonrFLaGqZQVm2z-mvZJOVdQEX7FVKR0HCVsqX7KJoRFG2sr5k94clmjncId-mzbcYzbRyP0Y-xTHNZkbuzOAw8jDwvY-BquxgYrAWzcAncuMwp498zyPOZJnQPQw0g-nXFBIfPZe14G4cErrloedMwvSavfCmT_jm8d2xn1effxy-ZDffrr8e9jeZK6Ges855K33nfSOgLSsE6BrhpBPCFQ0ahY1qwSrlqd1ZW9VStb6qlaiVtVKh3LH321wK9HvBNOtTSA773gw4LklDo6SsCkm4dqzcpI6CpIheTzGcTFw1CH3Gro96A6XP2DWAJuxke_e4YbEn7P6Z_nImwadNgJTzLmDUyRE2h12IhEt3Y3hqw_8DXB8GukX_C1dMx3GJhJuy6FRoob-fT3--PFRSVKKU8g-dJqv4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1853362315</pqid></control><display><type>article</type><title>Curative brachytherapy for prostate cancer in African-Caribbean patients: A retrospective analysis of 370 consecutive cases</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Atallah, V ; Leduc, N ; Creoff, M ; Sargos, P ; Taouil, T ; Escarmant, P ; Vinh-Hung, V</creator><creatorcontrib>Atallah, V ; Leduc, N ; Creoff, M ; Sargos, P ; Taouil, T ; Escarmant, P ; Vinh-Hung, V</creatorcontrib><description>Abstract Purpose Prostate cancer is the most frequent malignancy in African-Caribbean men, a population sharing common genetic traits with African-American (AA) but presenting also genomic and epidemiologic specificities. Despite socioeconomic disparities with French mainland, all patients were treated within the French state–financed equal-access health care system. In this study, we report biochemical outcomes of patients treated by brachytherapy in our department from 2005 to 2014 in an African-Caribbean population. Methods and Materials Three hundred seventy consecutive patients receiving125 I brachytherapy as a curative treatment for early-stage (localized) disease between 2005 and 2014 were recorded. Selected patients presented with low-risk disease: initial prostate-specific antigen (PSA) <10 ng/mL, clinical stage ≤ T2c, and Gleason score <7. Patients with intermediate risk of recurrence were also included on a case-to-case basis with prostate-specific antigen <15 or Gleason score 7 (3 + 4). Biochemical failure free–survival was defined according to the American Society for Radiation Oncology nadir+2 definition. Results The 3-year and 5-year biochemical failure free–survival for the entire cohort were 98.3% and 91.6%, respectively. For patients with low- and intermediate-risk disease, the 5-year BBFS rates were 92.1% and 90.8%, respectively. In univariate and multivariate analyses, only Gleason score (<7 vs. 7; p = 0.030 vs. p < 0.05) was a significant predictor of biochemical failure. The overall rate of late and acute Grade 2 or higher genitourinary toxicity was 12.6% and 10.3%. Conclusions In this large single-center series, brachytherapy achieved excellent rates of medium-term biochemical control in both low and selected intermediate-risk localized prostate cancer in African-Caribbean patients. Brachytherapy seems to be an excellent choice of treatment, with excellent outcomes and limited morbidity for African-Caribbean populations.</description><identifier>ISSN: 1538-4721</identifier><identifier>ISSN: 1873-1449</identifier><identifier>EISSN: 1873-1449</identifier><identifier>DOI: 10.1016/j.brachy.2016.11.006</identifier><identifier>PMID: 28024937</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; African-Caribbean ; Aged ; Black or African American ; Black People ; Brachytherapy ; Brachytherapy - adverse effects ; Disease-Free Survival ; Hematology, Oncology and Palliative Medicine ; Humans ; Iodine Radioisotopes - therapeutic use ; Male ; Martinique ; Middle Aged ; Neoplasm Grading ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - radiotherapy ; Racial disparity ; Radiology ; Retrospective Studies ; Risk Factors</subject><ispartof>Brachytherapy, 2017-03, Vol.16 (2), p.342-347</ispartof><rights>American Brachytherapy Society</rights><rights>2016 American Brachytherapy Society</rights><rights>Copyright © 2016 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-dcfb3fdff801946e11d80c3c00c28ea5e8591b55f019dbb67359f675075bb35e3</citedby><cites>FETCH-LOGICAL-c417t-dcfb3fdff801946e11d80c3c00c28ea5e8591b55f019dbb67359f675075bb35e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.brachy.2016.11.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28024937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Atallah, V</creatorcontrib><creatorcontrib>Leduc, N</creatorcontrib><creatorcontrib>Creoff, M</creatorcontrib><creatorcontrib>Sargos, P</creatorcontrib><creatorcontrib>Taouil, T</creatorcontrib><creatorcontrib>Escarmant, P</creatorcontrib><creatorcontrib>Vinh-Hung, V</creatorcontrib><title>Curative brachytherapy for prostate cancer in African-Caribbean patients: A retrospective analysis of 370 consecutive cases</title><title>Brachytherapy</title><addtitle>Brachytherapy</addtitle><description>Abstract Purpose Prostate cancer is the most frequent malignancy in African-Caribbean men, a population sharing common genetic traits with African-American (AA) but presenting also genomic and epidemiologic specificities. Despite socioeconomic disparities with French mainland, all patients were treated within the French state–financed equal-access health care system. In this study, we report biochemical outcomes of patients treated by brachytherapy in our department from 2005 to 2014 in an African-Caribbean population. Methods and Materials Three hundred seventy consecutive patients receiving125 I brachytherapy as a curative treatment for early-stage (localized) disease between 2005 and 2014 were recorded. Selected patients presented with low-risk disease: initial prostate-specific antigen (PSA) <10 ng/mL, clinical stage ≤ T2c, and Gleason score <7. Patients with intermediate risk of recurrence were also included on a case-to-case basis with prostate-specific antigen <15 or Gleason score 7 (3 + 4). Biochemical failure free–survival was defined according to the American Society for Radiation Oncology nadir+2 definition. Results The 3-year and 5-year biochemical failure free–survival for the entire cohort were 98.3% and 91.6%, respectively. For patients with low- and intermediate-risk disease, the 5-year BBFS rates were 92.1% and 90.8%, respectively. In univariate and multivariate analyses, only Gleason score (<7 vs. 7; p = 0.030 vs. p < 0.05) was a significant predictor of biochemical failure. The overall rate of late and acute Grade 2 or higher genitourinary toxicity was 12.6% and 10.3%. Conclusions In this large single-center series, brachytherapy achieved excellent rates of medium-term biochemical control in both low and selected intermediate-risk localized prostate cancer in African-Caribbean patients. Brachytherapy seems to be an excellent choice of treatment, with excellent outcomes and limited morbidity for African-Caribbean populations.</description><subject>Adult</subject><subject>African-Caribbean</subject><subject>Aged</subject><subject>Black or African American</subject><subject>Black People</subject><subject>Brachytherapy</subject><subject>Brachytherapy - adverse effects</subject><subject>Disease-Free Survival</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Male</subject><subject>Martinique</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Racial disparity</subject><subject>Radiology</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><issn>1538-4721</issn><issn>1873-1449</issn><issn>1873-1449</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v1DAQxS0EomXhGyDkI5cETxznDwek1YoWpEocgLNlO2PVSzYJdlIp6pdntikcuPRkj-a9Gb3fMPYWRA4Cqg_H3Ebjbte8oCoHyIWonrFLaGqZQVm2z-mvZJOVdQEX7FVKR0HCVsqX7KJoRFG2sr5k94clmjncId-mzbcYzbRyP0Y-xTHNZkbuzOAw8jDwvY-BquxgYrAWzcAncuMwp498zyPOZJnQPQw0g-nXFBIfPZe14G4cErrloedMwvSavfCmT_jm8d2xn1effxy-ZDffrr8e9jeZK6Ges855K33nfSOgLSsE6BrhpBPCFQ0ahY1qwSrlqd1ZW9VStb6qlaiVtVKh3LH321wK9HvBNOtTSA773gw4LklDo6SsCkm4dqzcpI6CpIheTzGcTFw1CH3Gro96A6XP2DWAJuxke_e4YbEn7P6Z_nImwadNgJTzLmDUyRE2h12IhEt3Y3hqw_8DXB8GukX_C1dMx3GJhJuy6FRoob-fT3--PFRSVKKU8g-dJqv4</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Atallah, V</creator><creator>Leduc, N</creator><creator>Creoff, M</creator><creator>Sargos, P</creator><creator>Taouil, T</creator><creator>Escarmant, P</creator><creator>Vinh-Hung, V</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170301</creationdate><title>Curative brachytherapy for prostate cancer in African-Caribbean patients: A retrospective analysis of 370 consecutive cases</title><author>Atallah, V ; Leduc, N ; Creoff, M ; Sargos, P ; Taouil, T ; Escarmant, P ; Vinh-Hung, V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-dcfb3fdff801946e11d80c3c00c28ea5e8591b55f019dbb67359f675075bb35e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>African-Caribbean</topic><topic>Aged</topic><topic>Black or African American</topic><topic>Black People</topic><topic>Brachytherapy</topic><topic>Brachytherapy - adverse effects</topic><topic>Disease-Free Survival</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Male</topic><topic>Martinique</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Racial disparity</topic><topic>Radiology</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Atallah, V</creatorcontrib><creatorcontrib>Leduc, N</creatorcontrib><creatorcontrib>Creoff, M</creatorcontrib><creatorcontrib>Sargos, P</creatorcontrib><creatorcontrib>Taouil, T</creatorcontrib><creatorcontrib>Escarmant, P</creatorcontrib><creatorcontrib>Vinh-Hung, V</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Brachytherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Atallah, V</au><au>Leduc, N</au><au>Creoff, M</au><au>Sargos, P</au><au>Taouil, T</au><au>Escarmant, P</au><au>Vinh-Hung, V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Curative brachytherapy for prostate cancer in African-Caribbean patients: A retrospective analysis of 370 consecutive cases</atitle><jtitle>Brachytherapy</jtitle><addtitle>Brachytherapy</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>16</volume><issue>2</issue><spage>342</spage><epage>347</epage><pages>342-347</pages><issn>1538-4721</issn><issn>1873-1449</issn><eissn>1873-1449</eissn><abstract>Abstract Purpose Prostate cancer is the most frequent malignancy in African-Caribbean men, a population sharing common genetic traits with African-American (AA) but presenting also genomic and epidemiologic specificities. Despite socioeconomic disparities with French mainland, all patients were treated within the French state–financed equal-access health care system. In this study, we report biochemical outcomes of patients treated by brachytherapy in our department from 2005 to 2014 in an African-Caribbean population. Methods and Materials Three hundred seventy consecutive patients receiving125 I brachytherapy as a curative treatment for early-stage (localized) disease between 2005 and 2014 were recorded. Selected patients presented with low-risk disease: initial prostate-specific antigen (PSA) <10 ng/mL, clinical stage ≤ T2c, and Gleason score <7. Patients with intermediate risk of recurrence were also included on a case-to-case basis with prostate-specific antigen <15 or Gleason score 7 (3 + 4). Biochemical failure free–survival was defined according to the American Society for Radiation Oncology nadir+2 definition. Results The 3-year and 5-year biochemical failure free–survival for the entire cohort were 98.3% and 91.6%, respectively. For patients with low- and intermediate-risk disease, the 5-year BBFS rates were 92.1% and 90.8%, respectively. In univariate and multivariate analyses, only Gleason score (<7 vs. 7; p = 0.030 vs. p < 0.05) was a significant predictor of biochemical failure. The overall rate of late and acute Grade 2 or higher genitourinary toxicity was 12.6% and 10.3%. Conclusions In this large single-center series, brachytherapy achieved excellent rates of medium-term biochemical control in both low and selected intermediate-risk localized prostate cancer in African-Caribbean patients. Brachytherapy seems to be an excellent choice of treatment, with excellent outcomes and limited morbidity for African-Caribbean populations.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28024937</pmid><doi>10.1016/j.brachy.2016.11.006</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1538-4721 |
| ispartof | Brachytherapy, 2017-03, Vol.16 (2), p.342-347 |
| issn | 1538-4721 1873-1449 1873-1449 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1853362315 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult African-Caribbean Aged Black or African American Black People Brachytherapy Brachytherapy - adverse effects Disease-Free Survival Hematology, Oncology and Palliative Medicine Humans Iodine Radioisotopes - therapeutic use Male Martinique Middle Aged Neoplasm Grading Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy Racial disparity Radiology Retrospective Studies Risk Factors |
| title | Curative brachytherapy for prostate cancer in African-Caribbean patients: A retrospective analysis of 370 consecutive cases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T00%3A41%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Curative%20brachytherapy%20for%20prostate%20cancer%20in%20African-Caribbean%20patients:%20A%20retrospective%20analysis%20of%20370%20consecutive%20cases&rft.jtitle=Brachytherapy&rft.au=Atallah,%20V&rft.date=2017-03-01&rft.volume=16&rft.issue=2&rft.spage=342&rft.epage=347&rft.pages=342-347&rft.issn=1538-4721&rft.eissn=1873-1449&rft_id=info:doi/10.1016/j.brachy.2016.11.006&rft_dat=%3Cproquest_cross%3E1853362315%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1853362315&rft_id=info:pmid/28024937&rft_els_id=1_s2_0_S1538472116306043&rfr_iscdi=true |